These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

750 related articles for article (PubMed ID: 27026375)

  • 1. Prevention of hepatitis B virus-associated liver diseases by antiviral therapy.
    Tawada A; Kanda T; Imazeki F; Yokosuka O
    Hepatol Int; 2016 Jul; 10(4):574-93. PubMed ID: 27026375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of hepatocellular carcinoma in hepatitis B virus infection.
    Lim SG; Mohammed R; Yuen MF; Kao JH
    J Gastroenterol Hepatol; 2009 Aug; 24(8):1352-7. PubMed ID: 19702903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of antiviral therapy in patients with chronic hepatitis B and cirrhosis.
    Okada M; Enomoto M; Kawada N; Nguyen MH
    Expert Rev Gastroenterol Hepatol; 2017 Dec; 11(12):1095-1104. PubMed ID: 28752768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of chronic hepatitis B infection.
    Sundaram V; Kowdley K
    BMJ; 2015 Oct; 351():h4263. PubMed ID: 26491030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcome of hepatitis B virus-related Chronic Hepatitis under protracted nucleos(t)ide analogues.
    Niro GA; Ippolito AM; Fontana R; Valvano MR; Gioffreda D; Iacobellis A; Merla A; Durazzo M; Lotti G; Di Mauro L; Andriulli A
    J Viral Hepat; 2013 Jul; 20(7):502-9. PubMed ID: 23730844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peginterferon Is Superior to Nucleos(t)ide Analogues for Prevention of Hepatocellular Carcinoma in Chronic Hepatitis B.
    Liang KH; Hsu CW; Chang ML; Chen YC; Lai MW; Yeh CT
    J Infect Dis; 2016 Mar; 213(6):966-74. PubMed ID: 26582959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does hepatitis B virus therapy reduce the risk of hepatocellular carcinoma?
    Ridruejo E
    Expert Opin Drug Saf; 2015 Mar; 14(3):439-51. PubMed ID: 25547687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Timing and selection of antiviral therapy with nucleos(t)ide analogues for prevention of hepatitis B virus-related HCC].
    Han C; Lai PP; Dou XG
    Zhonghua Gan Zang Bing Za Zhi; 2019 Nov; 27(11):827-830. PubMed ID: 31941235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs).
    Grossi G; Viganò M; Loglio A; Lampertico P
    Liver Int; 2017 Jan; 37 Suppl 1():45-51. PubMed ID: 28052621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver transplantation for hepatitis B virus: Decreasing indication and changing trends.
    Al-Hamoudi W; Elsiesy H; Bendahmash A; Al-Masri N; Ali S; Allam N; Al Sofayan M; Al Bahili H; Al Sebayel M; Broering D; Saab S; Abaalkhail F
    World J Gastroenterol; 2015 Jul; 21(26):8140-7. PubMed ID: 26185387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does antiviral therapy for chronic hepatitis B reduce the risk of hepatocellular carcinoma?
    Abu-Amara M; Feld JJ
    Semin Liver Dis; 2013 May; 33(2):157-66. PubMed ID: 23749672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of HBV therapy on the incidence of hepatocellular carcinoma.
    Triolo M; Della Corte C; Colombo M
    Liver Int; 2014 Feb; 34 Suppl 1():139-45. PubMed ID: 24373091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis B virus: from diagnosis to treatment.
    Dény P; Zoulim F
    Pathol Biol (Paris); 2010 Aug; 58(4):245-53. PubMed ID: 20580167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of chronic hepatitis B: status and challenges beyond treatment guidelines.
    Wiegand J; van Bömmel F; Berg T
    Semin Liver Dis; 2010 Nov; 30(4):361-77. PubMed ID: 20960376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short- and long-term outcome of interferon therapy for chronic hepatitis B infection.
    Seo Y; Yano Y
    World J Gastroenterol; 2014 Oct; 20(37):13284-92. PubMed ID: 25309065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Taiwan consensus statement on the management of chronic hepatitis B.
    Chien RN; Kao JH; Peng CY; Chen CH; Liu CJ; Huang YH; Hu TH; Yang HI; Lu SN; Ni YH; Chuang WL; Lee CM; Wu JC; Chen PJ; Liaw YF
    J Formos Med Assoc; 2019 Jan; 118(1 Pt 1):7-38. PubMed ID: 30527436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B Virus Combo Mutations Improve the Prediction and Active Prophylaxis of Hepatocellular Carcinoma: A Clinic-Based Cohort Study.
    Yin J; Wang J; Pu R; Xin H; Li Z; Han X; Ding Y; Du Y; Liu W; Deng Y; Ji X; Wu M; Yu M; Zhang H; Wang H; Thompson TC; Ni W; Cao G
    Cancer Prev Res (Phila); 2015 Oct; 8(10):978-88. PubMed ID: 26290395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of hepatocellular carcinoma: beyond hepatitis B vaccination.
    Kim MN; Han KH; Ahn SH
    Semin Oncol; 2015 Apr; 42(2):316-28. PubMed ID: 25843736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiviral therapy for chronic hepatitis B.
    Jafri SM; Lok AS
    Clin Liver Dis; 2010 Aug; 14(3):425-38. PubMed ID: 20638023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic hepatitis B and metabolic risk factors: A call for rigorous longitudinal studies.
    Seto WK
    World J Gastroenterol; 2019 Jan; 25(3):282-286. PubMed ID: 30686897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.